StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 22 Mar 2022 07:06:28 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday ObsEva SA (OBSV) Announces Additional Efficacy Results for Linzagolix 200 mg with ABT and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosi http://www.streetinsider.com/Corporate+News/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html for the full story. http://www.streetinsider.com/Corporate+News/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html Tue, 22 Mar 2022 07:06:28 -0500 OBSN OBSV ObsEva SA (OBSV) Announces Additional Efficacy Results for Linzagolix 200 mg with ABT and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosi http://www.streetinsider.com/Corporate+News/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html for the full story. http://www.streetinsider.com/Corporate+News/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html Tue, 22 Mar 2022 07:06:28 -0500 OBSN OBSV ObsEva SA (OBSV) Announces Additional Efficacy Results for Linzagolix 200 mg with ABT and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosi http://www.streetinsider.com/FDA/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html Visit StreetInsider.com at http://www.streetinsider.com/FDA/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html for the full story. http://www.streetinsider.com/FDA/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html Tue, 22 Mar 2022 07:06:28 -0500 OBSN OBSV ObsEva SA (OBSV) Announces Additional Efficacy Results for Linzagolix 200 mg with ABT and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosi http://www.streetinsider.com/FDA/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html Visit StreetInsider.com at http://www.streetinsider.com/FDA/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html for the full story. http://www.streetinsider.com/FDA/ObsEva+SA+%28OBSV%29+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+ABT+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+Endometriosi/19805221.html Tue, 22 Mar 2022 07:06:28 -0500 OBSN OBSV ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Tue, 22 Mar 2022 07:00:00 -0500 A.00641573 A.37955122 A.38055885 OBSN OBSV ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Tue, 22 Mar 2022 07:00:00 -0500 A.00641573 A.37955122 A.38055885 OBSN OBSV ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Tue, 22 Mar 2022 07:00:00 -0500 A.00641573 A.37955122 A.38055885 OBSN OBSV ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Tue, 22 Mar 2022 07:00:00 -0500 A.00641573 A.37955122 A.38055885 OBSN OBSV ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Tue, 22 Mar 2022 07:00:00 -0500 A.00641573 A.37955122 A.38055885 OBSN OBSV ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html for the full story. http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Tue, 22 Mar 2022 07:00:00 -0500 A.00641573 A.37955122 A.38055885 OBSN OBSV ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html for the full story. http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Tue, 22 Mar 2022 07:00:00 -0500 A.00641573 A.37955122 A.38055885 OBSN OBSV ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html for the full story. http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Tue, 22 Mar 2022 07:00:00 -0500 A.00641573 A.37955122 A.38055885 OBSN OBSV ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html for the full story. http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Tue, 22 Mar 2022 07:00:00 -0500 A.00641573 A.37955122 A.38055885 OBSN OBSV ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html for the full story. http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Additional+Efficacy+Results+for+Linzagolix+200+mg+with+Add-Back+Therapy+%28ABT%29+and+Linzagolix+75+mg+without+ABT+in+the+Phase+3+EDELWEISS+3+Trial+in+Patients+with+Moderate-to-Severe+End/19805088.html Tue, 22 Mar 2022 07:00:00 -0500 A.00641573 A.37955122 A.38055885 OBSN OBSV ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Press+Releases/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html for the full story. http://www.streetinsider.com/Globe+Newswire/ObsEva+Announces+Year+End+2021+Financial+Results+and+Provides+Corporate+Update/19755041.html Thu, 10 Mar 2022 07:00:00 -0500 A.04855241 A.06822034 A.31066700 A.37955122 A.38055885 A.60012004 OBSN OBSV OGN